<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02790489</url>
  </required_header>
  <id_info>
    <org_study_id>2015-A01864-45</org_study_id>
    <nct_id>NCT02790489</nct_id>
  </id_info>
  <brief_title>Tolerance Study of the Dietary Supplement Valedia</brief_title>
  <acronym>ECPH1-01</acronym>
  <official_title>Valedia Dietary Supplement Tolerance Study Based on Blood, Urinary and Hemodynamic Biological Parameters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valbiotis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre d'Investigation Clinique INSERM 501, Clermont-Ferrand, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Valbiotis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this clinical study are to determine the tolerance of dietary supplement
      Valedia (blend of plant extracts) through the evaluation of several parameters :

        -  Various blood biological parameters for tolerance (preprandial): blood glucose, insulin,
           fructosamine, total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol,
           oxidized LDL, us-CRP, creatinine, ASAT, ALAT, gGT, phosphatase alcaline, bilirubine,
           urea.

        -  Urinary parameters: urea, creatinine.

        -  Hemodynamic parameters: heart rate and blood pressure.

        -  Cardiac function: ECG.

        -  Weight.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on urine urea</measure>
    <time_frame>10 weeks</time_frame>
    <description>Urine urea</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on urine creatinine</measure>
    <time_frame>10 weeks</time_frame>
    <description>Urine creatinine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on fasting glycemia</measure>
    <time_frame>10 weeks</time_frame>
    <description>Fasting blood glucose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on insulin</measure>
    <time_frame>10 weeks</time_frame>
    <description>Plasma insulin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on fructosamine</measure>
    <time_frame>10 weeks</time_frame>
    <description>Blood fructosamine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on total cholesterol</measure>
    <time_frame>10 weeks</time_frame>
    <description>Blood total cholesterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on HDL cholesterol</measure>
    <time_frame>10 weeks</time_frame>
    <description>Blood HDL cholesterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on LDL cholesterol</measure>
    <time_frame>10 weeks</time_frame>
    <description>Blood LDL cholesterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on triglycerides</measure>
    <time_frame>10 weeks</time_frame>
    <description>Blood triglycerides</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on oxidized LDL cholesterol</measure>
    <time_frame>10 weeks</time_frame>
    <description>Blood oxidized LDL cholesterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on inflammation</measure>
    <time_frame>10 weeks</time_frame>
    <description>Blood us-CRP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on AST</measure>
    <time_frame>10 weeks</time_frame>
    <description>Blood AST</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on ALT</measure>
    <time_frame>10 weeks</time_frame>
    <description>Blood ALT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on gamma GT</measure>
    <time_frame>10 weeks</time_frame>
    <description>Blood gamma GT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on alkaline phosphatase</measure>
    <time_frame>10 weeks</time_frame>
    <description>Blood phosphatase alkaline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on bilirubin</measure>
    <time_frame>10 weeks</time_frame>
    <description>Blood bilirubin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect on cardiac function</measure>
    <time_frame>10 weeks</time_frame>
    <description>ECG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The response during an oral glucide tolerance test after a standardized breakfast</measure>
    <time_frame>10 weeks</time_frame>
    <description>Oral glucose tolerance test (after a standardized breakfast) with glycemia and insulinemia measurements (-10 min, -5 min, +15 min, +30 min, +45 min, +60 min, +90 min, +120 min, arrival at center in fasting state)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Valedia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 : 2,5 g (4 capsules) Valedia per day during 4 weeks Dose 2 : 5 g (8 capsules) Valedia per day during 4 weeks 2 weeks (wash-out period) between the 2 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Valedia</intervention_name>
    <arm_group_label>Valedia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  25 &lt;= BMI &lt; 30 kg.m2

        Main Exclusion Criteria:

          -  ASAT &lt;= 1,55 microkat/L

          -  ALAT &lt;= 1,70 microkat/L

          -  gGT &lt;= 2,55 microkat/L

          -  55 &lt;= Creatinine &lt;= 104 micromol/L (+- 10%)

          -  Bilirubin &lt; 17,1 micromol/L (+- 10%)

          -  1,7 &lt;= Urea &lt;= 8,3 mmol/L (+- 10%)

          -  us-CRP &lt;= 5 mg/L (+- 10%)

          -  0,70 &lt;= Fasting glycemia &lt;= 1,25 g/L (+- 10%)

          -  HbA1c &lt;= 6%

          -  Medications for diabetes and/or dyslipidemia
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sébastien L Peltier, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Valbiotis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>June 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2016</study_first_posted>
  <last_update_submitted>August 8, 2016</last_update_submitted>
  <last_update_submitted_qc>August 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

